[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"motor-neuron-disease-mnd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:motor-neuron-disease-mnd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100610866","healing-als-registry-observational-study-haros-100610866",false,"NCT07233148","Healing ALS Registry Observational Study (HAROS)","HAROS","Inclusion Criteria:\n\n* Diagnosed with ALS, MND or PLS\n\nExclusion Criteria:\n\n* Smokers","ALL","18 Years","110 Years",{"count":20,"type":21},1000,"ESTIMATED","10 Years","OBSERVATIONAL","This is a prospective, observational, online study of people diagnosed with ALS, MND or PLS referred to as HAROS (Healing ALS Registry Observational Study). Participants will enter information into an online ALS registry once per month, including their ALSFRS-R data, certain other symptoms, dietary intake, supplements, medications and other therapies, both conventional and integrative. Participants will also enter the hours spent on optional self-study and free online education. The investigators will assess the effectiveness of various therapies and education by measuring physical outcomes.",[26,27,28],"Amyotrophic Lateral Sclerosis (ALS)","Motor Neuron Disease (MND)","Primary Lateral Sclerosis (PLS)",[30,31,32,33,34,35,36],"ALS","PLS","MND","Amyotrophic Lateral Sclerosis","Primary Lateral Sclerosis","Motor Neuron Disease","Motor Neurone Disease","RECRUITING","2026-06-19",{"date":40,"type":41},"2026-06-24","ACTUAL",{"date":43,"type":41},"2026-01-26",{"date":45,"type":21},"2036-03-31",{"name":47,"class":48},"Healing Advocates Registry and Ministry","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100623452","phase-1-kamlanoflast-in-amyotrophic-lateral-sclerosis-100623452","NCT07396818","Kamlanoflast In Amyotrophic Lateral Sclerosis","A Trial of Kamlanoflast In Patients With Amyotrophic Lateral Sclerosis","Inclusion Criteria:\n\n1. Diagnosis of definite, probable, laboratory-supported probable, or possible ALS by revised El Escorial research criteria.\n2. Ages 18 to 75 years.\n3. Onset of weakness within three years of study enrollment.\n4. ALS with progression, characterized either by:\n\ni. a reduction of 0.5 points per month or greater on the ALS Functional Rating Scale-Revised (ALSFRS-R), which will be calculated based on (most recent ALSFRS-R at least 12 weeks from screening - ALSFRS-R at screening)\u002Ftime interval; or ii. a calculated progression rate: (48 - ALSFRS-R at \"time of diagnosis\") \u002F duration from onset to diagnosis (month) that is 0.5 points per month or greater.\n\ne) Plasma NfL levels ≥ 2 times the upper limit of the age-specific reference values for normal at the measuring laboratory at screening.\n\nf) Capable of providing informed consent. g) Capable and willing to follow study protocol. h) Ability to swallow pills and liquids at the time of the screening visit and, in the investigator's opinion have the ability to swallow for the duration of the study OR can be fed via a Gastrostomy (G) tube or Percutaneous Endoscopic capacity (PEG) tube.\n\ni) Slow vital capacity (SVC) \\> 65% of predicted value for gender, height, and age (participants perform SVC for three trials and the best SVC will be used).\n\nj) Females of childbearing potential must agree to abstain from sex or use adequate method of contraception for the duration of the study period and for 28 days after the last dose of study drug.\n\nk) Males must agree to abstain from sex or use adequate method of contraception for the duration of the study period and for 28 days after the last dose of study drug.\n\nl) If an approved therapy for ALS is used during the study, a steady dose must be used as follows: i. Participants who do not currently receive riluzole and do not plan to receive riluzole during the study period. Participants receiving riluzole are on a stable dose for at least 4 weeks before enrollment. Participants receiving riluzole are expected to remain on the same dose throughout the duration of the study.\n\nii. Participants who do not currently receive edaravone and do not plan to receive edaravone during the study period. Participants receiving edaravone must have completed at least 1 cycle of treatment before enrollment and are expected to continue edaravone treatment throughout the duration of the study.\n\nExclusion Criteria:\n\n1. Inability to follow the study protocol, based on the investigator's assessment.\n2. Pregnant or nursing women.\n3. Recently（within 28 days）received other experimental treatments.\n4. Presence of any active infections or inflammatory diseases at the time of enrollment that may confound the assessment of levels of inflammatory markers.\n5. Taking any medication or supplements with anti-inflammatory effects, including but not limited to prednisone, colchicine, or curcumin.\n6. Taking Qalsody (tofersen).\n7. Taking any medications containing nucleotide reverse transcriptase inhibitors (NRTIs), including but not limited to Abacavir, Emtricitabine, Lamivudine, or Zidovudine; trade names Atripla, Biktarvy, Cimduo, Combivir, Complera, Delstrigo, Descovy, Dovato, Emtriva, Epivir, Epzicom, Genvoya, Odefsey, Retrovir, Stribild, Symfi, Symtuza, Triumeq, Trizivir, Truvada, Ziagen.\n8. Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant, according to investigator's judgment (e.g., cardiovascular instability, systemic infection), or clinically significant laboratory abnormality.\n9. Clinically significant abnormal liver or kidney function at baseline (pre-dose). The following values \\[alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 times the upper limit of normal (ULN) or estimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m2\\] are exclusionary regardless of clinical symptoms.\n10. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the investigator's opinion.\n11. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years.\n12. Non-invasive ventilation, tracheostomy, oxygen supplementation for primary pulmonary pathology.\n13. Current \u002F anticipated need of diaphragm pacing system (DPS).\n14. History of prior AAV gene therapy for any indication;\n15. Presence of any clinically relevant diseases that, in the research team's opinion, would prevent the subject from completing the study, including but not limited to severe cognitive dysfunction or medical conditions other than ALS that affect physical function or life expectancy.\n16. Plan to move away from the study site within the next 6 months.","75 Years",{"count":59,"type":21},40,"INTERVENTIONAL",[62,63],"PHASE1","PHASE2","This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected.",[66,30,67,68,27],"ALS (Amyotrophic Lateral Sclerosis)","Neuro-Degenerative Disease","Neuro-Degenerative Diseases","NOT_YET_RECRUITING","2026-02-02",{"date":72,"type":41},"2026-02-09",{"date":74,"type":21},"2026-02",{"date":76,"type":21},"2027-01",{"name":78,"class":79},"Inflammasome Therapeutics","INDUSTRY",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":60,"phases":90,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":49},"100574916","the-study-evaluating-the-improvement-of-nutritional-status-and-frailty-with-silkworm-pupa-powder-among-patients-with-motor-neuron-disease-100574916","NCT06765499","The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease","A Prospective, Double-blind, Randomized Controlled Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Compared With Placebo Among Motor Neuron Disease","Inclusion Criteria:\n\n* Voluntarily participate in the clinical study, fully understand and be informed about the study, and sign the Informed Consent Form (ICF); willing to follow and capable of completing all trial procedures.\n* Gender is not limited, age at the time of signing ICF: ≥18 years old, ≤80 years old; if the ALS patient is at least 18 years old, then the weight must be over 40 kilograms.\n* Diagnosis conforms to the confirmed and probable ALS in the ALS2020 diagnostic criteria (Gold Coast Criteria).\n* Clinical, neurophysiological, or pathological examination confirms evidence of lower motor neuron involvement.\n* Frailty Phenotype scale (FP) ≥1.\n* Exclude other diseases.\n* Agree to provide peripheral blood, fecal, and urine samples for biomarker analysis during the study period.\n\nExclusion Criteria:\n\n* Patients with other neurological diseases similar to ALS symptoms or affecting drug efficacy evaluation, such as cervical spondylosis, lumbar disease, dementia, etc.\n* Patients with other autoimmune diseases, such as Multiple Sclerosis (MS), Polymyositis, Myasthenia Gravis, Guillain-Barré Syndrome, Ankylosing Spondylitis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Vitiligo, etc.\n* Severe renal insufficiency: Creatinine clearance \\\u003C 30 mL\u002Fmin (Cockcroft-Gault formula), or other known severe renal insufficiency diseases.\n* Severe liver damage: ALT, AST \\> 3 times the upper limit of normal, or other known liver diseases such as acute and chronic active hepatitis, cirrhosis, etc.\n* Patients with severe pulmonary function insufficiency such as Chronic Obstructive Pulmonary Disease (COPD), pulmonary fibrosis, etc.\n* During the screening period, patients with acute myocardial infarction or interventional treatment within the last 6 months, heart failure patients (classified as NYHA class III-IV patients).\n* Patients with other severe primary diseases of the nervous system, heart, lungs, hematopoietic system, or endocrine system, and mental illness patients.\n* Those suspected or confirmed to have a history of alcohol or drug abuse.\n* Expected survival ≤ 3 months.\n* Pregnant or breastfeeding women, subjects of reproductive age (including male subjects who have had heterosexual intercourse and their female partners with childbearing potential) who plan to become pregnant or are unwilling to take effective contraceptive measures from the start of screening to 3 months after discontinuing medication.\n* Those who are allergic to known ingredients of the trial products; or have a history of drug allergies or severe allergic diseases (anaphylactic shock, etc.).\n* During the study, individuals assessed by researchers as potential drug abusers who may affect the efficacy of therapeutic drugs.\n* Presence of other severe physical or mental diseases or abnormal laboratory tests that may increase the risk of participating in the study and patients deemed unsuitable for participation by the researcher.\n* Patients with malignant tumors.","80 Years",{"count":89,"type":21},100,[91],"NA","Motor Neuron Disease (MND) is the result of dysfunction of the upper motor neurons in the precentral gyrus of the frontal lobe or the lower motor neurons in the ventral horn of the spinal cord. Amyotrophic lateral sclerosis (ALS) is the most common, disabling, and fatal motor neuron disease in adults. Sarcopenia is a syndrome characterized by progressive loss of skeletal muscle mass, accompanied by a reduction in muscle strength and (or) function, and it is an important feature of MND. Aging is an objective and inevitable process that involves the gradual degeneration and loss of physiological functions in various tissues, organs, and cells. With the continuous accumulation of various injuries, the body eventually exhibits signs of frailty such as fatigue, reduced muscle strength, and weight loss. Data from adult ALS patients indicate that 58% of patients are at risk of frailty. Silkworm pupa contains high-quality animal protein and has a wide range of activities in antioxidant, antitumor, antibacterial, and immune enhancement, making it highly nutritious and medicinally valuable. Silkworm pupa extracts can enhance grip strength in older adults with relatively low skeletal muscle mass. As a natural food ingredient with high safety, the value of silkworm pupa in ALS patients lacks corresponding research, which limits its further application in clinical practice. This study aims to select ALS patients as the research subjects and use a randomized, controlled, double-blind prospective study design to evaluate the effectiveness of silkworm pupa tablets in improving sarcopenia, frailty, and quality of life in ALS patients. The study strives to improve the frailty condition of ALS patients and enhance their quality of life by supplementing nutrition, thereby providing new strategies for comprehensive intervention and management of ALS patients.",[27,26],[33,35,95,96],"Frailty","Nutritional Status","2025-04-30",{"date":99,"type":41},"2025-05-04",{"date":101,"type":41},"2025-03-04",{"date":103,"type":21},"2026-12-30",{"name":105,"class":48},"First People's Hospital of Hangzhou"]